Documents for the Ad Comm meeting were released this morning. Not very hopeful from ASTX’s point of view. They concluded that the pivotal trial failed to show a statistically significant improvement in overall survival in the Dacogen arm.
“Given that overall survival is the gold standard, we ask the Oncologic Drugs Advisory Committee to discuss the risks and benefits of Dacogen for the treatment of newly diagnosed AML in patients 65 and older”
There was an ad-hoc analysis that did show some statistical benefit but the document is dismissive of it. I off-loaded my remaining ASTX at the open at $2.50. So with yesterday’s sale my average realised price for ASTX is $2.67, a 67% return on my purchase price of $1.64.